Clinical Trial: Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma
Brief Summary: The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with cholangiocarcinoma.
Detailed Summary: The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with cholangiocarcinoma.
Sponsor: The First People's Hospital of Changzhou
Current Primary Outcome: Recurrence-free survival [ Time Frame: 1 year ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Adverse events [ Time Frame: 4 weeks ]
Original Secondary Outcome: Same as current
Information By: The First People's Hospital of Changzhou
Dates:
Date Received: June 24, 2015
Date Started: July 2012
Date Completion: July 2033
Last Updated: February 21, 2016
Last Verified: February 2016